Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its position in Twist Bioscience Co. (NASDAQ:TWST) by 4,418.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,925 shares of the company’s stock after purchasing an additional 4,816 shares during the quarter. International Assets Investment Management LLC’s holdings in Twist Bioscience were worth $223,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Signaturefd LLC increased its stake in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $61,000. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares in the last quarter.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,656 shares of company stock worth $1,791,419. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $45.42 on Thursday. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.89 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $15.85 and a 1-year high of $60.90. The company has a 50 day moving average price of $43.64 and a 200 day moving average price of $45.43.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TWST shares. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.